Varian, Inc. attracted to MR supplier
This article was originally published in The Gray Sheet
$32 mil. purchase of UK-based Magnex Scientific follows September acquisition of Digilab spectroscopy assets for $14 mil., marking step toward Varian's goal of executing $150 mil. in combinations over three years, Palo Alto firm says Oct. 11. Over that period, Varian aims to generate $1 bil. in annual revenue from scientific instruments and grow operating margins from 11% to 15%. "A trend of MR imaging has been ever-increasing field strength that requires larger and larger magnets," CEO Garry Rogerson explains. "If we are to integrate the magnets into the total system, we need to have control of the development and cost." The Magnex deal includes potential milestone payments for three years. Varian estimates Magnex shipments will total $25 mil.-$28 mil. over 12 months, with roughly 7%-8% likely to support scientific instruments R&D...
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.